Brand/other name
Alegra, Caladine, Caladryl, Calarex, Confortin, Herocyn, Mami Calacyn Lotion.
How it works
Calamine is a drug used as an anti-itch and anti-inflammatory agent for mild irritation, chickenpox (varicella), and prickly heat (miliaria) to insect bites. Calamine works by providing a cooling and soothing effect on the skin applied. These effects can relieve itching complaints caused by skin diseases.
Indication
"Medical conditions in the form of skin diseases that give a feeling of itching, for example, prickly heat (miliaria), mild irritation, chickenpox (varicella), to insect bites.
Contraindications
Contraindications to the use of calamine are a history of hypersensitivity or allergy to calamine or other components that are present in conjunction with calamine preparations (e.g., hives or swelling of the eyelids).
Side Effects
: Side effects are generally rare. However, there are some side effects that may occur, such as a burning sensation in the local area, hives, hives, itching, white patches (hypopigmentation), peeling skin, redness, swelling, pain, or other signs of irritation.
Preparation
A few Calamine preparations that can be found to date are as follows:
- : Diagnosis
: Diagnosis
Dosage for adults and children: applied to the itchy skin area 1 – 4 times a day for 5 – 7 days or until the complaint is felt to have improved, it can be reapplied after bathing or rinsing with water.
Security
Including FDA Category N (not clearly known about the harmful risk to the fetus) so it needs to be consulted first by a doctor in its use so that it can be monitored. However, the use of calamine is considered safe for pregnant women because calamine is only applied outside the body and is not absorbed systemically.
Drug Interactions
: No clinically meaningful reports are available to date regarding drug interactions that may occur when other drugs are used concomitantly with calamine. It is recommended to consult a doctor if other drugs are used concomitantly with calamine so that their use can be monitored.
